Panorama view of the Oxford skyline, with the Sheldonian Theatre, Bodleiain Library and St Mary's Church all visible against a blue sky. Credit: Shutterstock
Panorama view of the Oxford skyline, with the Sheldonian Theatre, Bodleiain Library and St Mary's Church all visible against a blue sky. Credit: Shutterstock - GlaxoSmithKline plc and the University of Oxford today announced a major five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine. The new Institute, which will be based at the University of Oxford, aims to improve the success and speed of research and development of new medicines, building on insights from human genetics and using advanced technologies such as functional genomics and machine learning. Genetic evidence has already been shown to double success rates in clinical studies of new treatments, and the digitisation of human biology has the potential to improve drug discovery by more closely linking genes to patients. The new Institute aims to build on this scientific progress and improve how diseases are understood by drawing on recent advances in pathology, including how to measure changes on a cellular, protein, or tissue level. Backed by £30 million from GSK, the Institute is intended to pioneer further improvements in how new medicines are discovered and developed. For example, scientists from GSK and Oxford will help prioritise those early R&D programmes most likely to succeed and match them to patients most likely to respond.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
